A Phase I Trial of Weekly 17-Allylamino-17 Demethoxygeldanamycin

This page presents selected fields from the linked source record. It does not add a medical interpretation.

Open original source record ↗

Record identity and dates

Source

ClinicalTrials.gov

Source record ID

NCT00004241

Title field or adapter rule

protocolSection.identificationModule.officialTitle

Ingested At

2026-04-28T10:35:22.092142+00:00

Published At

2013-02-07T00:00:00+00:00

Record Updated At

2013-02-07

Timestamp Basis

source retrieval time was not retained by the feed adapter

Date limitation

source retrieval time was not retained by the feed adapter

Fields recorded by this source

protocolSection.conditionsModule.conditions

["AIDS-related Peripheral/Systemic Lymphoma", "AIDS-related Primary CNS Lymphoma", "Anaplastic Large Cell Lymphoma", "Angioimmunoblastic T-cell Lymphoma", "Chondrosarcoma", "Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue", "Intraocular Lymphoma", "Metastatic Ewing Sarcoma/Peripheral Primitive Neuroectodermal Tumor", "Metastatic Osteosarcoma", "Nodal Marginal Zone B-cell Lymphoma", "Ovarian Sarcoma", "Primary Central Nervous System Non-Hodgkin Lymphoma", "Recurrent Adult Burkitt Lymphoma", "Recurrent Adult Diffuse Large Cell Lymphoma", "Recurrent Adult Diffuse Mixed Cell Lymphoma", "Recurrent Adult Diffuse Small Cleaved Cell Lymphoma", "Recurrent Adult Hodgkin Lymphoma", "Recurrent Adult Immunoblastic Large Cell Lymphoma", "Recurrent Adult Lymphoblastic Lymphoma", "Recurrent Adult Soft Tissue Sarcoma", "Recurrent Adult T-cell Leukemia/Lymphoma", "Recurrent Cutaneous T-cell Non-Hodgkin Lymphoma", "Recurrent Ewing Sarcoma/Peripheral Primitive Neuroectodermal Tumor", "Recurrent Grade 1 Follicular Lymphoma", "Recurrent Grade 2 Follicular Lymphoma", "Recurrent Grade 3 Follicular Lymphoma", "Recurrent Mantle Cell Lymphoma", "Recurrent Marginal Zone Lymphoma", "Recurrent Mycosis Fungoides/Sezary Syndrome", "Recurrent Osteosarcoma", "Recurrent Small Lymphocytic Lymphoma", "Recurrent Uterine Sarcoma", "Small Intestine Lymphoma", "Splenic Marginal Zone Lymphoma", "Stage IV Adult Burkitt Lymphoma", "Stage IV Adult Diffuse Large Cell Lymphoma", "Stage IV Adult Diffuse Mixed Cell Lymphoma", "Stage IV Adult Diffuse Small Cleaved Cell Lymphoma", "Stage IV Adult Hodgkin Lymphoma", "Stage IV Adult Immunoblastic Large Cell Lymphoma", "Stage IV Adult Lymphoblastic Lymphoma", "Stage IV Adult Soft Tissue Sarcoma", "Stage IV Adult T-cell Leukemia/Lymphoma", "Stage IV Cutaneous T-cell Non-Hodgkin Lymphoma", "Stage IV Grade 1 Follicular Lymphoma", "Stage IV Grade 2 Follicular Lymphoma", "Stage IV Grade 3 Follicular Lymphoma", "Stage IV Mantle Cell Lymphoma", "Stage IV Marginal Zone Lymphoma", "Stage IV Mycosis Fungoides/Sezary Syndrome", "Stage IV Small Lymphocytic Lymphoma", "Stage IV Uterine Sarcoma", "Unspecified Adult Solid Tumor, Protocol Specific"]

protocolSection.statusModule.lastUpdatePostDateStruct.date

"2013-02-07"

protocolSection.identificationModule.nctId

"NCT00004241"

protocolSection.identificationModule.officialTitle

"A Phase I Trial of Weekly 17-Allylamino-17 Demethoxygeldanamycin"

protocolSection.statusModule.overallStatus

"COMPLETED"

protocolSection.designModule.phases

["PHASE1"]

protocolSection.statusModule.resultsFirstPostDateStruct.date

""

Study condition terms

• AIDS-related Peripheral/Systemic Lymphoma (protocolSection.conditionsModule.conditions)
• AIDS-related Primary CNS Lymphoma (protocolSection.conditionsModule.conditions)
• Anaplastic Large Cell Lymphoma (protocolSection.conditionsModule.conditions)
• Angioimmunoblastic T-cell Lymphoma (protocolSection.conditionsModule.conditions)
• Chondrosarcoma (protocolSection.conditionsModule.conditions)
• Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue (protocolSection.conditionsModule.conditions)
• Intraocular Lymphoma (protocolSection.conditionsModule.conditions)
• Metastatic Ewing Sarcoma/Peripheral Primitive Neuroectodermal Tumor (protocolSection.conditionsModule.conditions)
• Metastatic Osteosarcoma (protocolSection.conditionsModule.conditions)
• Nodal Marginal Zone B-cell Lymphoma (protocolSection.conditionsModule.conditions)
• Ovarian Sarcoma (protocolSection.conditionsModule.conditions)
• Primary Central Nervous System Non-Hodgkin Lymphoma (protocolSection.conditionsModule.conditions)
• Recurrent Adult Burkitt Lymphoma (protocolSection.conditionsModule.conditions)
• Recurrent Adult Diffuse Large Cell Lymphoma (protocolSection.conditionsModule.conditions)
• Recurrent Adult Diffuse Mixed Cell Lymphoma (protocolSection.conditionsModule.conditions)
• Recurrent Adult Diffuse Small Cleaved Cell Lymphoma (protocolSection.conditionsModule.conditions)
• Recurrent Adult Hodgkin Lymphoma (protocolSection.conditionsModule.conditions)
• Recurrent Adult Immunoblastic Large Cell Lymphoma (protocolSection.conditionsModule.conditions)
• Recurrent Adult Lymphoblastic Lymphoma (protocolSection.conditionsModule.conditions)
• Recurrent Adult Soft Tissue Sarcoma (protocolSection.conditionsModule.conditions)
• Recurrent Adult T-cell Leukemia/Lymphoma (protocolSection.conditionsModule.conditions)
• Recurrent Cutaneous T-cell Non-Hodgkin Lymphoma (protocolSection.conditionsModule.conditions)
• Recurrent Ewing Sarcoma/Peripheral Primitive Neuroectodermal Tumor (protocolSection.conditionsModule.conditions)
• Recurrent Grade 1 Follicular Lymphoma (protocolSection.conditionsModule.conditions)
• Recurrent Grade 2 Follicular Lymphoma (protocolSection.conditionsModule.conditions)
• Recurrent Grade 3 Follicular Lymphoma (protocolSection.conditionsModule.conditions)
• Recurrent Mantle Cell Lymphoma (protocolSection.conditionsModule.conditions)
• Recurrent Marginal Zone Lymphoma (protocolSection.conditionsModule.conditions)
• Recurrent Mycosis Fungoides/Sezary Syndrome (protocolSection.conditionsModule.conditions)
• Recurrent Osteosarcoma (protocolSection.conditionsModule.conditions)
• Recurrent Small Lymphocytic Lymphoma (protocolSection.conditionsModule.conditions)
• Recurrent Uterine Sarcoma (protocolSection.conditionsModule.conditions)
• Small Intestine Lymphoma (protocolSection.conditionsModule.conditions)
• Splenic Marginal Zone Lymphoma (protocolSection.conditionsModule.conditions)
• Stage IV Adult Burkitt Lymphoma (protocolSection.conditionsModule.conditions)
• Stage IV Adult Diffuse Large Cell Lymphoma (protocolSection.conditionsModule.conditions)
• Stage IV Adult Diffuse Mixed Cell Lymphoma (protocolSection.conditionsModule.conditions)
• Stage IV Adult Diffuse Small Cleaved Cell Lymphoma (protocolSection.conditionsModule.conditions)
• Stage IV Adult Hodgkin Lymphoma (protocolSection.conditionsModule.conditions)
• Stage IV Adult Immunoblastic Large Cell Lymphoma (protocolSection.conditionsModule.conditions)
• Stage IV Adult Lymphoblastic Lymphoma (protocolSection.conditionsModule.conditions)
• Stage IV Adult Soft Tissue Sarcoma (protocolSection.conditionsModule.conditions)
• Stage IV Adult T-cell Leukemia/Lymphoma (protocolSection.conditionsModule.conditions)
• Stage IV Cutaneous T-cell Non-Hodgkin Lymphoma (protocolSection.conditionsModule.conditions)
• Stage IV Grade 1 Follicular Lymphoma (protocolSection.conditionsModule.conditions)
• Stage IV Grade 2 Follicular Lymphoma (protocolSection.conditionsModule.conditions)
• Stage IV Grade 3 Follicular Lymphoma (protocolSection.conditionsModule.conditions)
• Stage IV Mantle Cell Lymphoma (protocolSection.conditionsModule.conditions)
• Stage IV Marginal Zone Lymphoma (protocolSection.conditionsModule.conditions)
• Stage IV Mycosis Fungoides/Sezary Syndrome (protocolSection.conditionsModule.conditions)
• Stage IV Small Lymphocytic Lymphoma (protocolSection.conditionsModule.conditions)
• Stage IV Uterine Sarcoma (protocolSection.conditionsModule.conditions)
• Unspecified Adult Solid Tumor, Protocol Specific (protocolSection.conditionsModule.conditions)

Intervention details are not present in the imported fields for this record. No drug-condition relationship is inferred from co-listing.

This index keeps the source fields it imported; it may not contain the complete original record. Verify wording and context in the linked source.